利纳西珠单抗浓度而非 IL-22 水平与克罗恩病患者的临床和生化缓解相关。

Risankizumab Concentration but not IL-22 Levels Are Associated With Clinical and Biochemical Remission in Patients With Crohn's Disease.

机构信息

Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France; CIRI (Centre International de Recherche en Infectiologie), Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Saint-Etienne, France.

Immunology Laboratory, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France.

出版信息

Clin Gastroenterol Hepatol. 2024 Nov;22(11):2340-2343.e2. doi: 10.1016/j.cgh.2024.03.039. Epub 2024 May 4.

DOI:10.1016/j.cgh.2024.03.039

PMID:38705437

Abstract

Risankizumab (RZB) is a monoclonal antibody that targets the p19 subunit of interleukin (IL)-23. The ADVANCE and MOTIVATE randomized controlled trials (RCTs) demonstrated that intravenous (IV) RZB compared with placebo led to higher rates of clinical remission and endoscopic response at week 12 in patients with active Crohn's disease (CD). The phase III FORTIFY RCT showed that subcutaneous (SC) RZB was significantly more effective than placebo for achieving clinical remission and endoscopic response as maintenance therapy in patients with moderate-to-severe active CD..

摘要

里莎珠单抗（RZB）是一种靶向白细胞介素（IL）-23 的 p19 亚单位的单克隆抗体。ADVANCE 和 MOTIVATE 两项随机对照试验（RCT）表明，与安慰剂相比，静脉注射（IV）RZB 可使活动期克罗恩病（CD）患者在第 12 周时达到更高的临床缓解率和内镜缓解率。III 期 FORTIFY RCT 表明，在中重度活动期 CD 患者中，SC RZB 作为维持治疗在实现临床缓解和内镜缓解方面显著优于安慰剂。